Belgium-based Bone Therapeutics reported the 12-month efficacy results from the PREOB Phase IIA severe osteoporosis trial.
Here are five takeaways:
1. The results demonstrate a single administration of PREOB has positive effects on pain and osteoporosis blood markers.
2. The trial currently involves seven patients who don't respond to anti-osteoporotic therapy.
3. The patients experienced more than 40 percent decreases in pain. In comparison, patients receiving anabolic agent teriparatide saw a 30 percent decrease in pain.
4. Researchers found a decrease of more than 25 percent of bone resorption markers in an early phase of the 12-month follow-up.
5. The preliminary results suggest a single administration of PREOB stimulates bone remodeling, with a favorable bone formation-to-resorption ratio.